Compare Byrna Technologies Inc (BYRN) vs CVS Health Corp (CVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Byrna Technologies Inc vs CVS Health Corp — how do they compare? Byrna Technologies Inc trades at $3.57 (market cap $80.33M), while CVS Health Corp trades at $104.75 (market cap $135.48B). The key difference: CVS Health Corp is far larger — about 1686.5× Byrna Technologies Inc's market cap, and CVS Health Corp pays a 2.51% dividend while Byrna Technologies Inc pays none. Which is the better fit depends on your goals.
| BYRN | CVS | |
|---|---|---|
Market Cap | $80.33M | $135.48B |
Sector | Technology | Health |
52-Week High | $27.63 | $106.18 |
52-Week Low | $3.54 | $58.75 |
Enterprise Value | $71.94M | $202.02B |
Dividend Yield | — | 2.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BYRN trades at $3.82, down 1.16% today, with a bearish technical signal from moving averages. Recent Q2 2026 results showed a significant miss with a $0.44 EPS loss versus -$0.10 expected, amid a 42.5% revenue decline. The company is undergoing a marketing reset and acquired HERO Defense Systems to expand its product portfolio. Net income margin turned negative at -3.39% for 2026, though gross margin remains strong at 52.51%.
Outlook is cautious due to execution risks in sales turnaround efforts. Analyst consensus is bullish with 71% buy ratings, but near-term challenges in e-commerce traffic and conversion pose headwinds. The stock's valuation appears reasonable with P/S of 0.76, but profitability concerns and ongoing legal investigations present substantial risks for investors.
CVS Health trades at $105.9, up 1.68% recently, with a bullish technical signal and strong analyst support (84.6% buy ratings). The company has beaten earnings estimates for three consecutive quarters, including Q1 2026 EPS of $2.57 versus $2.18 expected. Revenue growth remains robust, reaching $402.07B in 2025, though net margins are thin at 0.72%. Recent news highlights a settlement with the FTC advancing prescription drug affordability initiatives.
The outlook is positive given earnings momentum and strategic positioning in healthcare services, but risks include regulatory pressures and margin compression. The consensus price target of $110.62 suggests modest upside from current levels, supported by dividend payments and institutional confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Byrna Technologies Inc
Byrna Technologies specializes in less-lethal personal security devices. It develops and manufactures innovative handheld launchers and projectiles designed for self-defense, law enforcement, and private security use.
Read more on BYRN →About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →
